CIS is a potent checkpoint in NK cell–mediated tumor immunity-Reference-Cited by-同舟云学术

CIS is a potent checkpoint in NK cell–mediated tumor immunity

Published:2016-05-23 Issue:7 Volume:17 Page:816-824
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Delconte Rebecca B,Kolesnik Tatiana B,Dagley Laura F,Rautela Jai,Shi Wei,Putz Eva M^ORCID,Stannard Kimberley,Zhang Jian-Guo,Teh Charis,Firth Matt,Ushiki Takashi,Andoniou Christopher E,Degli-Esposti Mariapia A,Sharp Phillip P,Sanvitale Caroline E,Infusini Giuseppe,Liau Nicholas P D,Linossi Edmond M,Burns Christopher J,Carotta Sebastian,Gray Daniel H D,Seillet Cyril,Hutchinson Dana S,Belz Gabrielle T,Webb Andrew I,Alexander Warren S,Li Shawn S,Bullock Alex N^ORCID,Babon Jeffery J^ORCID,Smyth Mark J,Nicholson Sandra E,Huntington Nicholas D^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni.3470.pdf

Reference61 articles.

1. Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).

2. Shin, D.S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33, 23–35 (2015).

3. Restifo, N.P., Smyth, M.J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121–126 (2016).

4. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252 (2012).

5. Huntington, N.D., Vosshenrich, C.A. & Di Santo, J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703–714 (2007).

Cited by 291 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML;Science Translational Medicine;2024-09-11

2. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

3. Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints;Science Advances;2024-08-30

4. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy;Frontiers in Immunology;2024-08-30

5. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy;Pharmaceutics;2024-08-29